Pharmaceutical Business Intelligence

Highlights

3/1/2026

Client feed
integration date

1.25M

Total audited
sales units

6 Yrs

Active historical
audited range

Verified ATC
drug classifications

17.8K

Weighted monthly
average units

Anatomical Therapeutic Chemical Class Performance

ATC Classification Code / Description	Historical Units Sold	Average Retail Price	Total Calculated Revenue	Percentage Share of Sales
M01AB — Non-Steroids, Acetic Acid derivatives	154,230	$28.50	$4,395,555.00	12.3%
M01AE — Non-Steroids, Propionic Acid derivatives	119,410	$18.25	$2,179,232.50	9.5%
N02BA — Other Analgesics and Antipyretics, Salicylic Acid	134,800	$12.00	$1,617,600.00	10.8%
N02BE — Other Analgesics and Antipyretics, Pyrazolones	565,220	$15.50	$8,760,910.00	45.2%
N05B — Psycholeptics, Anxiolytic Drugs	231,100	$42.00	$9,706,200.00	18.5%
N05C — Psycholeptics, Hypnotics and Sedatives	21,800	$58.00	$1,264,400.00	1.7%
R03 — Drugs for Obstructive Airway Diseases	116,400	$34.50	$4,015,800.00	9.3%
R06 — Antihistamines for Systemic Use	106,120	$14.25	$1,512,210.00	8.5%

[All pharmaceutical sales data audited as of May 31, 2026]

Clinical Volume Primacy

Since the client feed integration commencement in March 2026, our analytical suite audited a massive, non-null set of 1.25M sales units over the historical active range. Category N02BE (Pyrazolones/Anilides) remains the primary volume driver, contributing 45.2% ($8.76M) of total units, validating its massive customer mindshare.

Specialty Drug Price Power

Highlighters of the central nervous system portfolio like N05B (Anxiolytics) command high average prices of $42.00, representing the second largest share of revenue ($9.71M) despite representing just 18.5% of total sales volume.

Operational Note: Sales metrics are calculated strictly on raw unit velocities from verified Point-of-Sale ledgers, excluding public healthcare subsidies.

Temporal Trends

Hourly Peak Administration Demand

Intraday Prescription Cycles (Hourly Resampled)

Morning Opening Peak (08:00 - 10:00) High Demand

Mid-Day Lunch Rush (12:00 - 14:00) Maximum Peak

Post-Work Peak (17:00 - 19:00) Heavy Velocity

Late Night Refills (21:00 - 23:00) Low Density

Daily Ingestion Index (Weekly Resampled)

Weekdays (Monday - Friday) 82.5% of total units

Weekends (Saturday - Sunday) 17.5% of total units

Note: Data indicates substantial prescription fillings on weekday lunch hours, representing tight workplace population-density proximity.

Intraday Peak-Demand Shift Matrix

Morning Shift (08:00 - 12:00) 24.2% volume

Afternoon Shift (12:00 - 17:00) 45.8% volume

Evening Shift (17:00 - 21:00) 22.5% volume

Night Shift (21:00 - 08:00) 7.5% volume

Intraday Refill Frequency Variance Index

Weekday Lunch Rush Variance ± 3.4% [Extremely Consistent]

Weekend Afternoon Variance ± 12.8% [Highly Variable]

Refill variance measures transaction deviation from resampled hourly peaks, demonstrating extreme operational consistency during weekdays.

Intraday Purchase Peaks

Intraday sales data reveals a massive peak between 12:00 PM and 2:00 PM, accounting for 38% of daily retail volume. Operating schedules and shelf replenishment algorithms must target this sweet spot.

Weekday Dominance

Weekday transactions represent over four-fifths of sales volume. Corporate pharmacies should focus their staff scheduling and core delivery logistics on Monday-to-Wednesday windows to match this flow.

ATC Categories

Anti-Inflammatory & Analgesics Category Performance

Non-Steroid Anti-Inflammatory Split

M01AB — Acetic Acid derivatives 56.4% share

M01AE — Propionic Acid derivatives 43.6% share

Analgesics & Antipyretics Class Split

N02BE — Pyrazolones / Anilides 80.7% share

N02BA — Salicylic Acid derivatives 19.3% share

Psycholeptics & Sleep Regulation Intake

N05B — Anxiolytic Drugs 91.4% share

N05C — Hypnotics & Sedatives 8.6% share

Obstructive Airway & Antihistamine Volume

R03 — Drugs for Obstructive Airway 52.3% share

R06 — Antihistamines for Systemic Use 47.7% share

Therapeutic Cluster Velocity Matrix

Chronic Complex

Chronic Complex Care

Primary Categories: M01AB, R03.

Anchored by long-term respiratory therapies and prescription-strength acetic anti-inflammatories; exhibits stable, high-margin refill frequencies.

Acute Intermittent

Acute & OTC Fills

Primary Categories: M01AE, N02BE, R06.

High-velocity systemic antihistamines and propionic pain relief; heavily dependent on seasonal allergy cycles and cold/flu spikes.

Neurological Control

Central Nervous Control

Primary Categories: N05B, N05C.

Clinical anxiolytics and specialty sleep sedatives; commands maximum pricing power and extreme brand retention under tight audit controls.

Anilides vs Salicylates

Paracetamol (N02BE) dominates the pain segment over Aspirin (N02BA). This highlights the shift toward gentler systemic antipyretics in general prescription sales.

Central Nervous Control

Within the psycholeptics catalog, Anxiolytics (N05B) drive the largest portion of sales volume, leaving Hypnotics (N05C) as a specialized, low-density category. This represents an area with high margin returns but strict regulatory compliance.

Portfolio Composition

Therapeutic Class Share

N02BE Pyrazolones [45.2%]

N05B Anxiolytics [18.5%]

M01AB Acetic Acid [12.3%]

Other Classes [24.0%]

Pharma
Catalog

Retail Price Segmentation

Specialty / Premium (>$35) [41.2%]

Mid-Tier Therapy ($15-$35) [36.5%]

Generic / Budget (<$15) [22.3%]

Retail
Revenue

Year-over-Year (YoY) Growth & Velocity Trajectory

Therapeutic Class Code / Description	2020 Volume	2025 Volume	YoY CAGR Velocity	Traction Trend
N02BE — Pyrazolones / Anilides	92,500 units	118,200 units	+5.02%	↗ Sustained Primacy
N05B — Anxiolytic Drugs	34,200 units	48,500 units	+7.23%	↗ High Growth
M01AB — Acetic Acid derivatives	22,400 units	28,900 units	+5.22%	↗ Consistent Refills
R03 — Obstructive Airway Diseases	17,800 units	21,400 units	+3.75%	↗ Steady Baseline

Therapeutic Revenue Focus

Although Pyrazolones (N02BE) represent 45.2% of sales volume, premium specialty lines priced over $35 contribute 41.2% of total retail revenue. High-value prescription lines should be prioritised in marketing campaigns.

Generic Price Inelasticity

Sub-$15 generic drug classes demonstrate highly stable demand profiles, acting as a consistent volume buffer. Optimizing supply chains for these generic drugs secures steady baseline returns.

Seasonal Spikes

Seasonal Spikes & Product Volume Trends

N02BE (Paracetamol) Winter Volume Spike

Winter Peak (December - February) +142% volume

Summer Dip (June - August) Baseline

R06 (Antihistamines) Spring Allergy Surge

Spring Allergy Peak (March - May) +210% volume

Autumn Baseline (September - November) Baseline

Allergy Surge & Respiratory Inflow Heatmap Grid

Intraday Prescription Densities by Month (12-Month Inflow Audit)

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

NOV

DEC

Non-Steroid (M01)

Analgesics (N02)

Neurological (N05)

Respiratory (R03/R06)

Low Density

Medium Density

High Density

Supply Chain Procurement & Lead-Time Calculator

Interactive Safety Buffer Forecasting

Select Drug Classification

Calculator uses resampled monthly peak multipliers (e.g. +210% for R06, +142% for N02BE) and lead times to calculate the recommended safety stock buffers.

Active Pipeline

Recommended Ingestion Logistics Parameters

Safety Stock Buffer

736 units

Recommended Order

1,402 units

Wholesale Lead Time

14 Days

Total Ingest Capital

$19,979

30-Day Buffer

Immediate Action R06

Target Class: R06 (Antihistamines)
Safety Stock: +120% buffer
Status: Allergy surge impending. Trigger pre-emptive Loratadine/Cetirizine warehouse loading.

60-Day Buffer

Mid-Term Forecast N02BE

Target Class: N02BE (Paracetamol)
Safety Stock: +85% buffer
Status: Cold/flu winter spike preparation. Confirm paracetamol API contract pipeline allocations.

90-Day Buffer

Long-Term Strategic R03

Target Class: R03 (Airway Drugs)
Safety Stock: +50% buffer
Status: Chronic care asthma baseline hedging. Secure ocean-freight supply channels for cold-chain transit.

Respiratory Spikes

Obstructive airway therapies (R03) display acute demand increases in late spring (pollen surge) and mid-winter (influenza season), which requires maintaining safety stock levels throughout these high-velocity cycles.

Antihistamine Velocity

Systemic antihistamines (R06) experience a dramatic three-fold surge during spring allergy months, making a strong case for early promotional placement and robust wholesale inventory loading.

Regional Demographics

Geographic Distribution & Loyalty Indices

Market Penetration By Territory

North America [NA] 42% share

Europe [EU] 31% share

Asia-Pacific [APAC] 19% share

Latin America [LATAM] 8% share

Clinical Brand Regional Index

Drug Category	Primary Region	Loyalty Index
N02BE (Paracetamol)	Europe (EU)	4.92 / 5.00
N05B (Anxiolytics)	North America (NA)	4.81 / 5.00
R03 (Asthma Therapies)	Asia-Pacific (APAC)	4.68 / 5.00

Regional Compliance & Regulation Audit Matrix

FDA / North America

FDA Regulatory Zone

Compliance Status: Fully Compliant
Risk Index: Low (98% Audit Score)

Meets all federal oversight standards under national pharmaceutical tracking and clinical-efficacy disclosure parameters.

EMA / Europe

EMA Regulatory Zone

Compliance Status: Active Ingestion
Risk Index: Low-Med (94% Audit Score)

European Medicines Agency standards met across all localized product-shade cataloging and packaging compliance ledgers.

PMDA / Asia-Pacific

PMDA & TGA Zone

Compliance Status: Audited & Approved
Risk Index: Minimal (99% Audit Score)

Exceeds national clinical safety criteria under strict regional product verification protocols.

Weekly Co-Pay & Insurance Co-Insurance Ratios

Co-Pay Friction Indices by Class (Patient Share)

N05 Classes (Anxiolytics / Sedatives) 47.6% Patient Share

High patient out-of-pocket friction (average co-pay: $20.00 - $30.00).

M01 Classes (Non-Steroids) 35.1% Patient Share

Moderate co-pay friction (average co-pay: $10.00).

N02BE (Paracetamol) / Generics 0.0% Patient Share

Zero patient out-of-pocket friction (100% insurance/OTC coverage).

Weekly Insured Ingestion Flow Patterns

Weekday Insurance Ingestion Share (Mon-Fri) 84.5% [Optimal Flow]

Weekend Manual Override Share (Sat-Sun) 15.5% [High Latency]

Strategic Ingestion Point: High co-pay friction in psychiatric lines (N05 classes) leads to a 14.8% drop in weekend medication adherence due to insurance approval delay windows.

Geographic Strengths

North America continues to serve as the high-volume core for psychiatric therapies. Meanwhile, European markets exhibit the highest absolute retail loyalty indices for core pain management classes like Paracetamol (4.92).

APAC Obstructive Growth

Obstructive airway therapies demonstrate accelerating velocities in APAC urban centers, signaling a clear opportunity for localized product positioning and distribution expansions.

Diagnostics Database

Interactive Transactional Ledger

Timestamp	ATC Code	Pharmaceutical Brand	Sold Quantity	Unit Price	Total Revenue	Patient Co-Pay	Territory